Polymorph Control in Pharmaceutical Crystallization

Reference ID: MET-7316 | Process Engineering Reference Sheets Calculation Guide

Polymorph Control in Pharmaceutical Crystallization

Engineering Reference Sheet for Process Design & Optimization

Introduction & Context

Polymorph control in pharmaceutical crystallization is a critical process engineering task that ensures the consistent production of a drug substance in its desired crystalline form (polymorph). Different polymorphs exhibit distinct physicochemical properties (e.g., solubility, dissolution rate, and stability), which directly impact drug efficacy, safety, and manufacturability.

This reference sheet provides the theoretical framework and formulas to:

Calculate supersaturation ratios to drive nucleation and growth.
Predict polymorph transition temperatures using thermodynamic properties.
Estimate polymorph purity from X-ray diffraction (XRD) data.
Validate process conditions (cooling rates, residence times) for robust polymorph control.

Applications include:

Batch crystallization in drug substance manufacturing.
Process scale-up from lab to commercial production.
Quality by Design (QbD) for regulatory filings (e.g., ICH Q6A).
Troubleshooting polymorph impurities or batch-to-batch variability.

Methodology & Formulas

1. Supersaturation Ratio (\( S \))

The driving force for crystallization, defined as the ratio of actual solute concentration (\( C \)) to equilibrium solubility (\( C^* \)) at the process temperature:

\[ S = \frac{C}{C^*} \]

Regimes:

Supersaturation Range	Crystallization Behavior	Risk
S < 1.0	Undersaturated	No nucleation; dissolution may occur.
1.0 < S < 1.1	Metastable zone	Slow nucleation; growth-dominated.
1.1 < S < 10	Optimal nucleation/growth	None (target range).
S > 10	High supersaturation	Amorphous precipitation or uncontrolled nucleation.

2. Nucleation and Growth Kinetics

Empirical power-law models for primary nucleation (\( B \)) and crystal growth (\( G \)):

\[ B = k_n \cdot S^{n_{\text{nuc}}} \] \[ G = k_g \cdot S^{g} \]

where:

\( k_n \) = nucleation rate constant [nuclei/(m³·s)],
\( n_{\text{nuc}} \) = nucleation order [–],
\( k_g \) = growth rate constant [m/s],
\( g \) = growth order [–].

3. Polymorph Transition Thermodynamics

The transition temperature (\( T_{\text{trans}} \)) between two polymorphs (e.g., Form II → Form I) is derived from the equality of their Gibbs free energies (\( \Delta G = \Delta H - T \Delta S \)):

\[ T_{\text{trans}} = \frac{\Delta H_{\text{transition}}}{\Delta S_{\text{transition}}} \]

where:

\( \Delta H_{\text{transition}} \) = \( \Delta H_f^{\text{Form II}} - \Delta H_f^{\text{Form I}} \) [J/mol],
\( \Delta S_{\text{transition}} \) = \( \Delta S_f^{\text{Form II}} - \Delta S_f^{\text{Form I}} \) [J/(mol·K)].

Process Implications:

Temperature Relative to \( T_{\text{trans}} \)	Stable Polymorph	Crystallization Strategy
T ≫ \( T_{\text{trans}} \)	Form I (high-temperature polymorph)	Avoid; cool rapidly through \( T_{\text{trans}} \).
T < \( T_{\text{trans}} \)	Form II (low-temperature polymorph)	Maintain slow cooling to favor Form II.

4. Polymorph Purity by X-Ray Diffraction (XRD)

The polymorph ratio (\( \text{PR} \)) is estimated from XRD peak intensities (\( I \)) of characteristic reflections for each form:

\[ \text{PR} = \frac{I_{\text{Form II}}}{I_{\text{Form I}}} \]

The mass fraction of Form II (\( x_{\text{Form II}} \)) is calculated using reference intensities (\( I_{\text{ref}} \)) for 100% pure forms:

\[ x_{\text{Form II}} = \frac{\text{PR} \cdot I_{\text{ref, Form I}}}{\text{PR} \cdot I_{\text{ref, Form I}} + I_{\text{ref, Form II}}} \times 100\% \]

Purity Criteria:

Polymorph Ratio (\( \text{PR} \))	Form II Purity	Process Acceptability
PR < 5	< 80%	Unacceptable; adjust conditions.
5 < PR < 20	80–95%	Marginal; investigate outliers.
PR > 20	> 95%	Optimal; proceed to scale-up.

5. Process Validation Checks

Critical conditions to ensure robust polymorph control:

Parameter	Criterion	Rationale
Supersaturation Ratio (\( S \))	1.1 ≤ \( S \) ≤ 10	Avoids amorphous precipitation or no nucleation.
Final Temperature (\( T_{\text{final}} \))	T_final < \( T_{\text{trans}} \)	Ensures thermodynamic stability of Form II.
Residence Time (\( t_{\text{res}} \))	t_res ≥ 1.1 × \( t_{\text{cooling}} \)	Allows complete crystallization (10% buffer).
Cooling Time (\( t_{\text{cooling}} \))	\( t_{\text{cooling}} = \frac{T_{\text{initial}} - T_{\text{final}}}{\text{cooling rate}} \)	Must match residence time to avoid premature termination.

6. Cooling Rate Design

The linear cooling rate (\( \dot{T} \)) is defined as:

\[ \dot{T} = \frac{T_{\text{initial}} - T_{\text{final}}}{t_{\text{cooling}}} \]

Cooling Rate Guidelines:

Cooling Rate (\( \dot{T} \))	Impact on Polymorph Control	Typical Application
< 0.1 °C/min	Slow; favors thermodynamic stability (Form II)	Seed-mediated crystallization.
0.1–1.0 °C/min	Moderate; balanced nucleation/growth	Batch crystallization (default).
> 1.0 °C/min	Fast; risk of kinetic trapping (Form I)	Avoid unless rapid quenching is required.

Use in-line Raman or XRPD probes inserted directly into the vessel. Raman gives molecular fingerprint changes within seconds, while XRPD quantifies crystal lattice differences. Combine either with multivariate analytics (e.g., PCA on spectra) to trigger alarms when characteristic peaks move or new peaks appear. Calibrate against off-line DSC or PXRD to confirm the transition temperature and solvent composition limits.

Supersaturation trajectory: Program a linear or parabolic cooling ramp that keeps the system in the metastable zone of the desired form; 5–15 °C h⁻¹ often works for cooling crystallizations.
Seed loading & quality: Add 1–3 wt% of the target polymorph with narrow particle size (D50 ≈ 20–50 µm) at 5–10 °C below saturation to lock in the correct lattice.
Anti-solvent rate: Limit addition to ≤ 0.5 % v/v min⁻¹ to avoid local high supersaturation that nucleates the undesired form.
Residence time in transition zone: Keep slurry above the transition temperature for < 30 min to prevent solvent-mediated transformation.

Map the thermodynamic and kinetic stability windows first. If the desired form is enantiotropic (stable at higher T), use temperature cycling to stay above the transition point, then cool slowly. If the form is monotropic or stable only at high supersaturation, prefer anti-solvent addition at constant temperature to bypass the temperature range where the undesired form is stable. Confirm with slurry competition experiments: suspend both polymorphs in the final solvent composition for 24 h; the phase that grows or remains is the one your chosen method should favor.

A two-sensor PAT tier suffices: in-line Raman for polymorph identity and FBRM for chord length distribution to detect secondary nucleation. Validate Raman against off-line PXRD using a design space approach (ICH Q8) that links Raman peak intensity ratios to polymorphic purity. Store spectra as raw data in the batch record; FDA reviewers accept this if the calibration model (PLS or PCA) is locked before process validation and remains frozen post-approval.

Worked Example: Polymorph Control in Pharmaceutical Crystallization

Scenario

A pharmaceutical manufacturer is producing drug X in a batch crystallizer. The objective is to maximize the yield of the stable polymorph Form II while suppressing the metastable Form I. The process operates by cooling a supersaturated solution from 60 °C to 20 °C at a rate of 0.5 °C min⁻¹, with a residence time of 60 s in the crystallizer.

Knowns

Boltzmann constant \(k_{\text{BOLTZMANN}} = 1.381 \times 10^{-23}\) J K⁻¹
Gas constant \(R_{\text{GAS}} = 8.314\) J mol⁻¹ K⁻¹
Nucleation prefactor \(k_{\text{n}} = 1.000 \times 10^{8}\) s⁻¹
Critical nucleus size \(n_{\text{nuc}} = 2\)
Growth rate constant \(k_{\text{g}} = 1.000 \times 10^{-7}\) m s⁻¹
Growth exponent \(g_{\text{growth}} = 1\)
Enthalpy of fusion Form II \(\Delta H_{f,\text{FormII}} = 3.000 \times 10^{4}\) J mol⁻¹
Enthalpy of fusion Form I \(\Delta H_{f,\text{FormI}} = 2.800 \times 10^{4}\) J mol⁻¹
Entropy of fusion Form II \(\Delta S_{f,\text{FormII}} = 70.0\) J mol⁻¹ K⁻¹
Entropy of fusion Form I \(\Delta S_{f,\text{FormI}} = 65.0\) J mol⁻¹ K⁻¹
Reference nucleation rate Form II \(I_{\text{ref,FormII}} = 1.000 \times 10^{3}\) m⁻³ s⁻¹
Reference nucleation rate Form I \(I_{\text{ref,FormI}} = 5.000 \times 10^{1}\) m⁻³ s⁻¹
Initial temperature \(T_{\text{initial}} = 60.0\) °C
Final temperature \(T_{\text{final}} = 20.0\) °C
Cooling rate \(= 0.5\) °C min⁻¹
Initial concentration \(C_{\text{initial}} = 50.0\) g L⁻¹
Solubility at 20 °C \(C^{*}_{20°C} = 10.0\) g L⁻¹
Residence time \(= 60.0\) s
Transition temperature \(T_{\text{transition}} = 45.0\) °C
Measured nucleation rates: \(I_{\text{meas,FormII}} = 950\) m⁻³ s⁻¹, \(I_{\text{meas,FormI}} = 25\) m⁻³ s⁻¹
Supersaturation ratio \(S = 5.0\)
Bulk modulus \(B = 2.500 \times 10^{9}\) Pa
Growth coefficient \(G = 5.000 \times 10^{-7}\) m s⁻¹
Transition enthalpy \(\Delta H_{\text{transition}} = 2.000 \times 10^{3}\) J mol⁻¹
Transition entropy \(\Delta S_{\text{transition}} = 5.0\) J mol⁻¹ K⁻¹
Calculated transition temperature \(T_{\text{transition,calc}} = 400.0\) K (126.850 °C)
Polymorph ratio (Form II fraction) \(= 38.0\%\)

"Un projet n'est jamais trop grand s'il est bien conçu." — André Citroën

"La difficulté attire l'homme de caractère, car c'est en l'étreignant qu'il se réalise." — Charles de Gaulle